LCD Reference Article Response To Comments Article

Response to Comments: MolDX DecisionDX Uveal

A55561

Expand All | Collapse All

Contractor Information

Contractor Name	Contract Type	Contract Number	Jurisdiction	States
CGS Administrators, LLC	MAC - Part A	15101 - MAC A	J - 15	Kentucky
CGS Administrators, LLC	MAC - Part B	15102 - MAC B	J - 15	Kentucky
CGS Administrators, LLC	MAC - Part A	15201 - MAC A	J - 15	Ohio
CGS Administrators, LLC	MAC - Part B	15202 - MAC B	J - 15	Ohio

Article Information

General Information

Article ID
A55561

Article Title
Response to Comments: MolDX DecisionDX Uveal

Article Type
Response to Comments

Original Effective Date
07/10/2017

Retirement Date
N/A

AMA CPT / ADA CDT / AHA NUBC Copyright Statement

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Copyright © 2023, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Article Guidance

Article Text
The comment period for the MolDX: DecisionDx-UM (Uveal Melanoma) (LCD) DL37130 began on 02/16/2017 and ended on 04/03/2017. Comments were received from
the provider community. The notice period begins on 05/25/2017 and ends 07/09/2017. The LCD becomes final on 07/10/2017.

Response To Comments

Number	Comment	Response
1	I use this gene expression profile test as part of my routine work-up for uveal melanoma patients, and I believe that the result is an important component of their patient care. Knowing their DecisionDx Class allows me to adjust their imaging schedule so that it is appropriate for their metastatic risk. I also work closely with a medical oncologist at Duke, who sees my Class 1B and Class 2 patients due to their higher risk of disease spread.	Supportive comments noted. No comments against coverage of this assay.
2	This test has been validated in numerous studies for its ability to accurately predict metastatic potential in patients with uveal melanoma. This is allowed tailored screening for high-risk patients. Additionally tailored screening allows referral to oncology services at an earlier stage and gives patients the ability to understand their risk of metastasis and potentially allows earlier intervention for metastatic disease.	Supportive comments noted. No comments against coverage of this assay.
3	At our center, the multidisciplinary melanoma team recommends bi-annual systemic surveillance for patients at intermediate or high risk for metastatic disease (class 1B and 2 patients), with MRI liver and CT chest, whereas for low risk class 1A patients, liver ultrasound and chest x-ray is preferred. Furthermore, a Class 2 patient would also see our melanoma medical oncologist. It is important in this rare disease setting to have as much information about a patient’s risk as possible and this test is a critical component of that risk assessment.	Supportive comments noted. No comments against coverage of this assay.
4	I have presented my own series of more than 200 patients that confirmed the clinical performance of the test. The draft local coverage determination for DecisionDx-UM that you have issued is important for Medicare patients, as this test helps us decide what the best follow-up plan is with imaging, liver function testing, and the appropriate frequency of these tests based on metastatic risk.	Supportive comments noted. No comments against coverage of this assay.
5	The clinical utility of the test is to determine which patients are high-risk and should receive close, frequent screening in an effort to detect metastatic disease as early as possible but also to prevent low-risk patients from getting frequent imaging that they will likely not benefit from. I also send my intermediate (Class 1B) and high risk (Class 2) patients to see a medical oncologist so that they have a pre-existing relationship if they ultimately experience metastasis.	Supportive comments noted. No comments against coverage of this assay.
6	I participated in the original prospective validation of the test and since then several studies have confirmed that the test is accurate in predicting metastatic risk. Therefore, the test result can be used to inform a metastatic screening plan that matches the biological risk of the patient, with Class 1 patients having lessfrequent screening compared to Class 2 patients, who need more frequent screening and may also be eligible for an adjuvant therapy trial.	Supportive comments noted. No comments against coverage of this assay.
7	I offer this test to my uveal melanoma patients and then subsequently use the results to guide how frequently the patient has metastatic screening. I also encourage all of my Class 2 patients to see a medical oncologist who specializes in uveal melanoma and has access to an adjuvant clinical trial if they should want adjuvant treatment. Although not all Class 2 patients will have the means or desire to travel to see a medical oncologist, I do recommend this and as an alternative, their primary care physician or myself can perform their surveillance locally to monitor for metastasis.	Supportive comments noted. No comments against coverage of this assay.
8	The most important impact of the test result is that it helps to guide the post-treatment surveillance of the patient with increased surveillance (i.e. more frequent imaging) for Class 2 patients and lessened surveillance for Class 1 patients. I prefer that all my patients see a medical oncologist to manage their surveillance, while I focus on their eye care follow-up. However, given that I see some patients who are traveling long distances for their medical care and/or are among underserved patient populations, if they cannot feasibly see a medical oncologist, I will then prescribe their surveillance myself or work directly with their primary care physician to do so. Either way, the surveillance the patient receives reflects the risk associated with their DecisionDx-UM result.	Supportive comments noted. No comments against coverage of this assay.
9	I use DecisionDx-UM routinely for my uveal melanoma patients and the test results are critical for determining surveillance intensity, which is usually managed by a medical oncologist or, in rare cases where the patient cannot realistically see a medical oncologist due to geographic location, by me. In either case, Class 2 patients receive higher intensity surveillance while Class 1 patients receive lower intensity surveillance. The test results are also beneficial for Class 2 patients who are seeking clinical trials, as there are two trials currently enrolling for adjuvant treatment based on a Class 2 result.	Supportive comments noted. No comments against coverage of this assay.
10	Comments 10 - 12, summarizes the comments Noridian received for Draft Local Coverage Determinations DL37070 (JE)/DL37072 (JF) MolDX: DecisionDx-UM (Uveal Melanoma). A. It is reassuring to see the draft local coverage determination for DecisionDx-UM. This test is widely used in the United States for newly diagnosed uveal melanoma patients. I used it routinely in my prior practice at Duke University and will continue to use it in my new position at Stanford University, so I am glad to see that the test will be covered for Medicare patients. I participated in the original prospective validation of the test and since then several studies have confirmed that the test is accurate in predicting metastatic risk. Therefore, the test result can be used to inform a metastatic screening plan that matches the biological risk of the patient, with Class 1 patients having less frequent screening compared to Class 2 patients, who need more frequent screening and may also be eligible for an adjuvant therapy trial. Thank you for providing coverage for this important test, and I hope that longer term coverage will be considered given its importance in prognostication for uveal melanoma. B. I was encouraged after reading the draft LCD for DecisionDx-UM for Medicare patients. I use gene expression profiling regularly at the Casey Eye Institute/OHSU to guide decisions regarding systemic surveillance for metastatic disease after the patient’s eye is treated. At our center, the multidisciplinary melanoma team recommends bi-annual systemic surveillance for patients at intermediate or high risk for metastatic disease (class 1B and 2 patients), with MRI liver and CT chest, whereas for low risk class 1A patients, liver ultrasound and chest x-ray is preferred. Furthermore, a Class 2 patient would also see our melanoma medical oncologist. It is important in this rare disease setting to have as much information about a patient’s risk as possible and this test is a critical component of that risk assessment. Thank you for your coverage of this test and I hope that coverage will be extended. C. I would like to comment on the Draft LCD for DecisionDx-UM gene expression profiling for uveal melanoma. I am happy to see that the test will be covered for Medicare patients, and I would encourage Palmetto to consider long-term coverage of the test as well. The clinical utility of the test is to determine which patients are high-risk and should receive close, frequent screening in an effort to detect metastatic disease as early as possible but also to prevent low-risk patients from getting frequent imaging that they will likely not benefit from. I also send my intermediate (Class 1B) and high risk (Class 2) patients to see a medical oncologist so that they have a pre-existing relationship if they ultimately experience metastasis. However, there may be cases where I may need to provide the follow up management of these patients and would appreciate if that option be made available the final LCD. The LCD policy is reassuring to me that my patients will continue to be able to have this test as part of their routine care. D. In effect, it is very encouraging that the test is viewed as important and will be covered. I hope that you will also consider its long-term coverage based on its utility in my practice that I have described. E. At the University of Michigan, I use DecisionDx-UM routinely for prognostication in my patients with uveal melanoma, and I have presented my own series of more than 200 patients that confirmed the clinical performance of the test. The draft local coverage determination for DecisionDx-UM that you have issued is important for Medicare patients, as this test helps us decide what the best follow-up plan is with imaging, liver function testing, and the appropriate frequency of these tests based on metastatic risk. Considering that numerous physicians, including myself, have utilized this test for several years and consider it standard-ofcare, I recommend that the test should be covered in the future as well. F. I was pleased to hear that you are considering coverage for the decision DX uveal melanoma test. This test has been validated in numerous studies for its ability to accurately predict metastatic potential in patients with uveal melanoma. This is allowed tailored screening for high-risk patients. Additionally tailored screening allows referral to oncology services at an earlier stage and gives patients the ability to understand their risk of metastasis and potentially allows earlier intervention for metastatic disease. This test is a vital portion of the care given to my patients with uveal melanoma. I sincerely hope that you will approve coverage for this necessary test. G. I am writing to comment on the Draft Local Coverage Determination for DecisionDx-UM. It is very encouraging to see that this gene expression test for uveal melanoma will be covered for Medicare patients. I use DecisionDx-UM routinely for my uveal melanoma patients and the test results are critical for determining surveillance intensity, which is usually managed by a medical oncologist or, in rare cases where the patient cannot realistically see a medical oncologist due to geographic location, by me. In either case, Class 2 patients receive higher intensity surveillance while Class 1 patients receive lower intensity surveillance. The test results are also beneficial for Class 2 patients who are seeking clinical trials, as there are two trials currently enrolling for adjuvant treatment based on a Class 2 result.	Noridian appreciates the input.
11	Coverage indications and guidelines, limitations, and/or Medical Necessity (page 2) Text in draft LCD states: “…This test is intended for the determination of metastatic risk and to guide surveillance and referral to medical oncology…” Based on feedback from the physician specialists who routinely care for uveal melanoma patients (who order and utilize the test results), they do frequently refer to medical oncology, but occasionally there may be medical or logistical reasons why a referral may not be optimal. Therefore we would suggest adding the opportunity for ophthalmology physicians who specialize in treating patients with uveal melanoma to have the option to continue managing these patients if referral to medical oncology is not the optimal approach. Please note that these physicians who specialize in treating patients with uveal melanoma often manage metastatic surveillance plans if a patient is not able to be managed by medical oncology for surveillance. The suggested language would read as follows: Suggested text: …This test is intended for the determination of metastatic risk and to guide surveillance and referral to medical oncology or continued management by an ophthalmologist with experience in the management of uveal melanoma. Clinical Performance Utility (page 6) Text in draft LCD states: “…Continued coverage is dependent on the publication and/or presentation of clinical utility data demonstrating, for example, that at least 80% of class 2 patients are referred to medical oncology for management…” We would also suggest that based on input from physician specialists who treat this disease that the referral percentage be adjusted to 70%. Suggested text: …Continued coverage is dependent on the publication and/or presentation of clinical utility data demonstrating, for example, that at least 70% of class 2 patients are referred to medical oncology for management…” We would also suggest that based on input from physician specialists who treat this disease that the referral percentage be adjusted to 70%. Suggested text: …Continued coverage is dependent on the publication and/or presentation of clinical utility data demonstrating, for example, that at least 70% of class 2 patients are referred to medical oncology. ICD-10 Codes (Page 8) The draft LCD excluded three ICD-10 codes that are also used by ophthalmologists who specialize in treating patients with uveal melanoma. We request inclusion of all appropriate ICD-10 codes that are currently used to bill this test and other uveal melanoma related procedures to both Medicare and private insurers. These are: C69.30 Malignant neoplasm of unspecified choroid C69.31 Malignant neoplasm of right choroid C69.32 Malignant neoplasm of left choroid C69.40 Malignant neoplasm of unspecified ciliary body C69.41 Malignant neoplasm of right ciliary body C69.42 Malignant neoplasm of left ciliary body C69.90 Malignant neoplasm of unspecified site of unspecified eye C69.91 Malignant neoplasm of unspecified site of right eye C69.92 Malignant neoplasm of unspecified site of left eye CPT Code (Page 7) We request a change of the billing CPT code from 81599 (Unlisted Multianalyte Assay with Algorithmic Analysis) to 84999 (Miscellaneous Chemistry), which is the code outlined in the Noridian DecisionDx-UM billing guideline (effective January 1, 2017). References (Page 6) We provide the following references which appear in the Clinical Performance: Utility table, but are not listed in the reference section. Aaberg, T.M., Jr., et al., Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. Clin Ophthalmol, 2014. 8: p. 2449-60. Plasseraud, K.M., et al., Clinical Performance and Management Outcomes with the DecisionDx-UM Gene Expression Profile Test in a Prospective Multicenter Study. Journal of Oncology, 2016. 2016: p. 1-9. We commend this LCD, which guarantees that Medicare beneficiaries who are diagnosed with Uveal Melanoma will have access to this important, standard of care test, that informs patient management, and appreciate your consideration of these suggested modifications.	Medical oncologist: The following has been added to the DecisionDx-Um Test Description and Intended Use: “In rare cases where the patient cannot realistically see a medical oncologist due to geographic location (long distance to travel), and/or are among underserved patient populations, if they cannot feasibly see a medical oncologist, surveillance testing for class 2 patients can be directed by the ophthalmologist physician who specialize in treating patients with uveal melanoma or work directly with their primary care physician to do so.” Clinical Utility: This contractor recognizes that patient variables may contribute to less than 100% compliance with referral to a medical oncologist. Eighty percent (80%) is a generally accepted level of compliance for class 2 patients. It is a desired goal, not an absolute cutoff. ICD-10 codes: C69.30 Malignant neoplasm of unspecified choroid, C69.40 Malignant neoplasm of unspecified ciliary body, and C69.90 Malignant neoplasm of unspecified site of unspecified eye are non-specific and will not be added to the policy. The purpose of ICD-10 is to provide diagnosis specificity. References: The following references were inadvertently omitted from the reference list and have been added to the policy: Aaberg, T.M., Jr., et al., Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. Clin Ophthalmol, 2014. 8: p. 2449-60. Plasseraud, K.M., et al., Clinical Performance and Management Outcomes with the DecisionDx-UM Gene Expression Profile Test in a Prospective Multicenter Study. Journal of Oncology, 2016. 2016: p. 1-9.
12	The draft LCD for DecisionDx-UM is important for Medicare patients with uveal melanoma who benefit from this prognostic test. I would like to give my support for this LCD, because I offer this test to my uveal melanoma patients and then subsequently use the results to guide how frequently the patient has metastatic screening. I also encourage all of my Class 2 patients to see a medical oncologist who specializes in uveal melanoma and has access to an adjuvant clinical trial if they should want adjuvant treatment. Although not all Class 2 patients will have the means or desire to travel to see a medical oncologist, I do recommend this and as an alternative, their primary care physician or myself can perform their surveillance locally to monitor for metastasis. It will be very beneficial for Medicare patients to have this test covered so that we have this important piece of information to use develop their follow-up plan.	In the DecisionDx-UM Test Description and Intended Use, the following has been added to the policy: In rare cases where the patient cannot realistically see a medical oncologist due to geographic location (long distance to travel), and/or are among underserved patient populations, if they cannot feasibly see a medical oncologist, surveillance testing for class 2 patients can be directed by the ophthalmologist physician who specialize in treating patients with uveal melanoma or work directly with their primary care physician to do so.

Coding Information

CPT/HCPCS Codes

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-CM Codes that Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-CM Codes that DO NOT Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-PCS Codes

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

Additional ICD-10 Information

Bill Type Codes

Code	Description

Revenue Codes

Code	Description

Coding Table Information

Excluded CPT/HCPCS Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion
			N/A	N/A

Non-Excluded CPT/HCPCS Ended Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion

Revision History Information

N/A

Associated Documents

Related Local Coverage Documents
LCDs
L37130 - MolDX: DecisionDx-UM (Uveal Melanoma)

Updated On	Effective Dates	Status
05/18/2017	07/10/2017 - N/A	Currently in Effect	You are here

Keywords

N/A

Read the Article Disclaimer

Please review and accept the agreements in order to view Medicare Coverage documents, which may include licensed information and codes.

LICENSE FOR USE OF PHYSICIANS' CURRENT PROCEDURAL TERMINOLOGY, FOURTH EDITION ("CPT")

End User Point and Click Amendment:

CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the American Medical Association (AMA).

You, your employees and agents are authorized to use CPT only as agreed upon with the AMA internally within your organization within the United States for the sole use by yourself, employees and agents. Use is limited to use in Medicare, Medicaid or other programs administered by the Centers for Medicare and Medicaid Services (CMS). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized herein must be obtained through the AMA, CPT Intellectual Property Services, AMA Plaza 330 N. Wabash Ave., Suite 39300, Chicago, IL 60611-5885. Applications are available at the AMA Web site, http://www.ama-assn.org/go/cpt.

Applicable FARS\DFARS Restrictions Apply to Government Use.

AMA Disclaimer of Warranties and Liabilities.

CPT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CPT. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this file/product is with CMS and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice if you violate its terms. The AMA is a third party beneficiary to this Agreement.

CMS Disclaimer

The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT should be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CPT. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL CONTAINED ON THIS PAGE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Should the foregoing terms and conditions be acceptable to you, please indicate your agreement and acceptance by clicking below on the button labeled "I Accept".

LICENSE FOR USE OF CURRENT DENTAL TERMINOLOGY (CDT^TM)

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. By clicking below on the button labeled "I accept", you hereby acknowledge that you have read, understood and agreed to all terms and conditions set forth in this agreement.

If you do not agree with all terms and conditions set forth herein, click below on the button labeled "I do not accept" and exit from this computer screen.

If you are acting on behalf of an organization, you represent that you are authorized to act on behalf of such organization and that your acceptance of the terms of this agreement creates a legally enforceable obligation of the organization. As used herein, "you" and "your" refer to you and any organization on behalf of which you are acting.

Subject to the terms and conditions contained in this Agreement, you, your employees and agents are authorized to use CDT only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT for resale and/or license, transferring copies of CDT to any party not bound by this agreement, creating any modified or derivative work of CDT, or making any commercial use of CDT. License to use CDT for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the American Dental Association web site, http://www.ADA.org.
Applicable Federal Acquisition Regulation Clauses (FARS)/Department of Defense Federal Acquisition Regulation supplement (DFARS) Restrictions Apply to Government Use. U.S. Government Rights Provisions.
Organizations who contract with CMS acknowledge that they may have a commercial CDT license with the ADA, and that use of CDT codes as permitted herein for the administration of CMS programs does not extend to any other programs or services the organization may administer and royalties dues for the use of the CDT codes are governed by their commercial license.
ADA DISCLAIMER OF WARRANTIES AND LIABILITIES. CDT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CDT. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for software, including any CDT and other content contained therein, is with CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement.

The ADA is a third party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT should be addressed to the ADA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CDT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material covered by this license. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I Accept". If you do not agree to the terms and conditions, you may not access or use software. Instead you must click below on the button labeled "I Do Not Accept" and exit from this computer screen.

License For Use of National Uniform Billing Committee (NUBC) UB-04

These materials contain NUBC Official UB-04 Specifications (UB-04 Data), which is copyrighted by the American Hospital Association (AHA).

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING BELOW ON THE BUTTON LABELED "I ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK BELOW ON THE BUTTON LABELED "I DO NOT ACCEPT" AND EXIT FROM THIS COMPUTER SCREEN. IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

Subject to the terms and conditions contained in this Agreement, you, your employees, and agents are authorized to use UB-04 Data only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of UB-04 Data is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this Agreement. You acknowledge that the AHA holds all copyright, trademark, and other rights in UB-04 Data. You shall not remove, alter, or obscure any AHA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including, by way of illustration and not by way of limitation, making copies of UB-04 Data for resale and/or license, transferring copies of UB-04 Data to any party not bound by this agreement, creating any modified or derivative work of UB-04 Data, or making any commercial use of UB-04 Data. License to use UB-04 Data for any use not authorized herein must be obtained through the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois, 60606. Applications are available at the NUBC website, http://www.nubc.org/.
The UB-04 Data included in this product is commercial technical data and/or computer databases and/or commercial computer software and/or commercial computer software documentation, as applicable, which was developed exclusively at private expense by the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois 60606. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (November 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.
AHA DISCLAIMER OF WARRANTIES AND LIABILITIES. UB-04 Data is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. The sole responsibility for the software, including any UB-04 Data and other content contained therein, is with the Medicare/Medicaid Contractor or the CMS; and no endorsement by the AHA is intended or implied. The AHA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The AHA is a third-party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the AHA, the copyright holder. Any questions pertaining to the license or use of the UB-04 Data should be addressed to the AHA. End users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE UB-04 DATA. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Submit Feedback/Ask a Question

Response to Comments: MolDX DecisionDX Uveal

Document Note

Note History

Contractor Information

Article Information

General Information

CMS National Coverage Policy

Article Guidance

Response To Comments

Coding Information

Bill Type Codes

Revenue Codes

CPT/HCPCS Codes

Group 1

CPT/HCPCS Modifiers

Group 1

ICD-10-CM Codes that Support Medical Necessity

Group 1

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

ICD-10-PCS Codes

Group 1

Additional ICD-10 Information

Bill Type Codes

Revenue Codes

Other Coding Information

Group 1

Coding Table Information

Revision History Information

Associated Documents

Keywords

Page Help for Article - Response to Comments: MolDX DecisionDX Uveal (A55561)

Introduction

Finding a specific code

More information

Printing a Document to PDF

Get email updates

CMS & HHS WEBSITES

HELPFUL LINKS

RSS FEEDS